Compare Stocks

Stoke Therapeutics (($STOK)) has held its Q3 earnings call. Read on for the main highlights of the call. Stoke Therapeutics delivered a predominantly positive earnings call, highlighting strong Phase III

Reports Q3 revenue $11.3M, consensus $8.2M. “The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when

Stoke Therapeutics (STOK) announced two presentations of data for STK-002 at the American Academy of Ophthalmology, AAO, 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a

Stoke Therapeutics (STOK) announced two presentations of data for STK-002 at the American Academy of Ophthalmology, AAO, 2026 Annual Meeting, taking place October 9-12 in New Orleans. TK-002 is an

Oppenheimer initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $15 price target. The firm believes Camp4’s $190M EV discounts strategic interest in developmental/epileptic encephalopathies and represents a

Stoke Therapeutics (STOK) announced the completion of a successful meeting with the U.S. Food and Drug Administration, FDA, intended to align on key aspects of the Company’s planned submission of

Stoke Therapeutics ( ($STOK) ) just unveiled an update. On September 22, 2026, Stoke Therapeutics director Edward M. Kaye, M.D. informed the board of his decision to resign as a

Stoke Therapeutics (STOK) “announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo’s appointment, Edward Kaye, M.D., has retired from his role as a Director

“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9 in Athens, Greece. These data support the potential of

Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-in-class